Beta-thalassemia surgery: Difference between revisions
No edit summary |
|||
| (15 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Beta-thalassemia}} | {{Beta-thalassemia}} | ||
{{CMG}}; {{AE}} {{MHP}} | |||
==Overview== | |||
Surgical intervention is frequently required to guarantee optimum management of the accompanying morbidity in beta-thalassemia cases. The most prevalent types of surgical interventions associated with beta-thalassemia include [[splenectomy]], [[cholecystectomy]], leg ulcers, fractures, and extramedullary pseudotumor. | |||
==Surgery== | |||
Surgical intervention is frequently required to guarantee optimum management of the accompanying morbidity in beta-thalassemia cases. Before undergoing surgical intervention, there are a few things of a more general nature that need to be taken into mind: | |||
*[[Anemia]] | |||
*[[Cardiovascular disease]] | |||
*Thromboembolic events | |||
*The consequences of iron overload | |||
The most prevalent types of surgical interventions associated with beta-thalassemia include: | |||
*[[Splenectomy]]: In severe cases with significant [[splenomegaly]], splenectomy may be considered. This would help improve [[anemia]] and reduce transfusion requirements. | |||
*[[Cholecystectomy]]: Recurrent [[gallstone]] due to chronic [[hemolysis]]. | |||
*Leg ulcers | |||
*Fractures | |||
*Extramedullary pseudotumor<ref name="pmid21480198">{{cite journal |vauthors=Saad GS, Musallam KM, Taher AT |title=The surgeon and the patient with β-thalassaemia intermedia |journal=Br J Surg |volume=98 |issue=6 |pages=751–60 |date=June 2011 |pmid=21480198 |doi=10.1002/bjs.7533 |url=}}</ref><ref name="pmid34738740">{{cite journal |vauthors=Ali S, Mumtaz S, Shakir HA, Khan M, Tahir HM, Mumtaz S, Mughal TA, Hassan A, Kazmi SAR, Sadia, Irfan M, Khan MA |title=Current status of beta-thalassemia and its treatment strategies |journal=Mol Genet Genomic Med |volume=9 |issue=12 |pages=e1788 |date=December 2021 |pmid=34738740 |pmc=8683628 |doi=10.1002/mgg3.1788 |url=}}</ref><ref name="pmid31030806">{{cite journal |vauthors=Khandros E, Kwiatkowski JL |title=Beta Thalassemia: Monitoring and New Treatment Approaches |journal=Hematol Oncol Clin North Am |volume=33 |issue=3 |pages=339–353 |date=June 2019 |pmid=31030806 |doi=10.1016/j.hoc.2019.01.003 |url=}}</ref>. | |||
==References== | ==References== | ||
Latest revision as of 05:57, 25 August 2023
|
Beta-thalassemia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Beta-thalassemia surgery On the Web |
|
American Roentgen Ray Society Images of Beta-thalassemia surgery |
|
Risk calculators and risk factors for Beta-thalassemia surgery |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Maryam Hadipour, M.D.[2]
Overview
Surgical intervention is frequently required to guarantee optimum management of the accompanying morbidity in beta-thalassemia cases. The most prevalent types of surgical interventions associated with beta-thalassemia include splenectomy, cholecystectomy, leg ulcers, fractures, and extramedullary pseudotumor.
Surgery
Surgical intervention is frequently required to guarantee optimum management of the accompanying morbidity in beta-thalassemia cases. Before undergoing surgical intervention, there are a few things of a more general nature that need to be taken into mind:
- Anemia
- Cardiovascular disease
- Thromboembolic events
- The consequences of iron overload
The most prevalent types of surgical interventions associated with beta-thalassemia include:
- Splenectomy: In severe cases with significant splenomegaly, splenectomy may be considered. This would help improve anemia and reduce transfusion requirements.
- Cholecystectomy: Recurrent gallstone due to chronic hemolysis.
- Leg ulcers
- Fractures
- Extramedullary pseudotumor[1][2][3].
References
- ↑ Saad GS, Musallam KM, Taher AT (June 2011). "The surgeon and the patient with β-thalassaemia intermedia". Br J Surg. 98 (6): 751–60. doi:10.1002/bjs.7533. PMID 21480198.
- ↑ Ali S, Mumtaz S, Shakir HA, Khan M, Tahir HM, Mumtaz S, Mughal TA, Hassan A, Kazmi S, Sadia, Irfan M, Khan MA (December 2021). "Current status of beta-thalassemia and its treatment strategies". Mol Genet Genomic Med. 9 (12): e1788. doi:10.1002/mgg3.1788. PMC 8683628 Check
|pmc=value (help). PMID 34738740 Check|pmid=value (help). Vancouver style error: initials (help) - ↑ Khandros E, Kwiatkowski JL (June 2019). "Beta Thalassemia: Monitoring and New Treatment Approaches". Hematol Oncol Clin North Am. 33 (3): 339–353. doi:10.1016/j.hoc.2019.01.003. PMID 31030806.